Clinical Characteristics of Patients With Anti-Collapsin Response Mediator Protein 2 Antibodies in Encephalitis or Encephalomyelitis

The inclusion criteria for patients are illustrated: 1) patients admitted to the Department of Neurology,or the Neurocritical Unit (NCU) of Nanfang Hospital, Southern Medical University, between January 2017 and November 2019; 2) patients with suspected immune-mediated encephalopathy (altered consciousness persisting for more than 24 hours) or myelopathy. This included cases of encephalopathy suspected to be autoimmune, infectious or metabolic as well as encephalopathy with unclear etiology; 3) patients with remaining serum and/or cerebrospinal fluid (CSF) samples available for immunoreaction analysis using tissue-based assay (TBA) and cell-based assay (CBA). All samples were the first obtained from patients after hospitalization, prior to initiating treatment at our hospital. Some patients, however, may have received treatment at other hospitals before being transferred here.

The exclusion criteria were: 1) loss to follow-up; 2) incomplete data; 3) encephalopathy resulting from toxic, traumatic, anoxic/hypoxic, genetic, or endocrine causes.